Cargando…
Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study
Effective, low-cost therapeutics are needed to prevent and treat COVID-19. Severe COVID-19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases. We investig...
Autores principales: | Fillmore, Nathanael, Bell, Steven, Shen, Ciyue, Nguyen, Vinh, La, Jennifer, Dubreuil, Maureen, Strymish, Judith, Brophy, Mary, Mehta, Gautam, Wu, Hao, Lieberman, Judy, Do, Nhan, Sander, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553043/ https://www.ncbi.nlm.nih.gov/pubmed/34710137 http://dx.doi.org/10.1371/journal.pone.0259061 |
Ejemplares similares
-
Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals
por: Vo, Austin D., et al.
Publicado: (2022) -
Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study
por: Fillmore, Nathanael R, et al.
Publicado: (2020) -
Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation
por: La, Jennifer, et al.
Publicado: (2022) -
Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study
por: Li, Lucy L., et al.
Publicado: (2022) -
Risk factors of SARS-CoV-2 infection and complications from COVID-19 in lung cancer patients
por: Ganti, Apar Kishor, et al.
Publicado: (2023)